Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Executive Summary

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Advertisement

Related Content

Keeping Track: Some Calm Before The Storm
Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands
After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100457

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel